The relating factors of metabolic syndrome to benign prostatic hyperplasia

Korean Journal of Urology

Volumn 46, Issue 10, 2005, Pages 1046-1050

  Kim, Jae Hun ^a   Shim, Bong Suk ^a   Hong, Young Sun ^a  

^a Ewha Womans University School of Medicine   (South Korea)

Author keywords

Benign prostatic hyperplasia (BPH); Metabolic syndrome

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; EARLY DIAGNOSIS; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MICTURITION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREVALENCE; PROBABILITY; PROSTATE HYPERTROPHY; SENESCENCE;

EID: 27944490290     PISSN: 04944747     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Boon TA, Van Venrooij GE, Eckhardt MD. Effect of diabetes mellitus on lower urinary tract symptoms and dysfunction in patients with benign prostatic hyperplasia. Curr Urol Rep 2001;2:297-301
2. Michel MC, Heemann U, Schumacher H, Mehlburger L, Goepel M. Association of hypertension with symptoms of benign prostatic hyperplasia. J Urol 2004;172:1390-3
3. Hammarsten J, Hogstedt B, Holthuis N, Mellstrom D. Components of the metabolic syndrome-risk factors for the development of benign prostatic byperplasia. Prostate Cancer Prostatic Dis 1998;1:157-62
4. Hammarsten J, Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 2001;39: 151-8
5. Matsuda T, Abe H, Suda K. Relation between benign prostatic hyperplasia and obesity and estrogen. Rinsho Byori 2004;52: 291-4
6. Zaroli A, Mandressi A, Belloni M, Antonelli D, Bernasconi S, Buizza C, et al. Physiopathology of BPH obstruction. Arch Ital Urol Androl 1995;67:13-6
7. Hammarsten J, Hogstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press 1999;8:29-36
8. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991; 338:469-71
9. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486-97
10. Horton R, Hsieh P, Barberia J, Pages L, Cosgrove M. Altered blood androgens in elderly men with prostate hyperplasia. J Clin Endocrinol Metab 1975;41:793-6
11. Ishimaru T, Pages L, Horton R. Altered metabolism of androgens in elderly men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1977;45:695-701
12. Brochu M, Belanger A. Comparative study of plasma steroid and steroid glucuronide levels in normal men and in men with benign prostatic hyperplasia. Prostate 1987;11:33-40
13. McNeal J. Pathology of benign prostatic hyperplasia. Insight into etiology. Urol Clin North Am 1990;17:477-86
14. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silvershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47
15. Fuster V, Pearson TA. 27th Bethesda conference. Matching the intensity of risk factor management with the hazard for coronary disease events. J Am Coll Cardiol 1996;27:957-1047
16. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607
17. Nugent AP. The metabolic syndrome. BNF Nutr Bull 2004; 29:36-43
18. Lym YL, Hwang SW, Shim HJ, Oh EH, Chang YS, Cho BL. Prevalence and risk factors of the metabolic syndrome as defined by NCEP-ATPIII. J Korean Acad Fam Med 2003; 24:135-43
19. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-94
20. Rett K, Wicklmayr M, Mehnert H. New aspects of insulin resistance in hypertension. Eur Heart J 1994;15(Suppl C);78-81
21. Landsberg L. Diet, obesity and hypertension: an hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis. Q J Med 1986;61:1081-90
22. Berne C, Pollare T, Fagius J. The sympathetic outflow in vasoconstrictor nerve fascicles to muscle is increased during euglycacemic hyperinsulinemia. Diabetologia 1989;32(Suppl): 465A
23. Shieh SM, Sheu WH, Shen DC, Fuh MM, Chen YD, Reaven GM. Glucose, insulin, and lipid metabolism in doxazosin-treated patients with hypertension. Am J Hypertens 1992;5: 827-31
24. Pollare T, Lithell H, Selinus I, Berne C. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 1988;31:415-20
25. Swislocki AL, Hoffman BB, Sheu WH, Chen YD, Reaven GM. Effect of prazosin treatment on carbohydrate and lipoprotein metabolism in patients with hypertension. Am J Med 1989;86:14-8